In a game-changing shift for the biotech industry, the Federal Circuit has markedly broadened the scope of the International Trade Commission (ITC) as a viable litigation venue for life sciences companies. This ruling has profound implications for the sector, notably in terms of intellectual property protection and market competitiveness. Historically, the stringent economic domestic industry […]